Losartan Legal and Patent Challenges

FDA Approval and Early Regulatory Milestones

Losartan potassium received FDA approval on April 14, 1995, under NDA 020386, making it the first angiotensin II receptor blocker available to U.S. prescribers. Merck marketed the drug as Cozaar (losartan alone) and Hyzaar (losartan/hydrochlorothiazide combination). The approval covered treatment of hypertension in adults, with later label expansions for diabetic nephropathy and stroke risk reduction.

The original new drug application relied on Phase III data showing losartan 50 to 100 mg daily reduced sitting diastolic blood pressure by 8 to 10 mmHg compared with placebo. Unlike ACE inhibitors, losartan did not produce bradykinin-mediated cough, which became a core differentiator in prescribing decisions. The FDA's Drugs@FDA database lists the complete approval history, including three supplemental NDAs that expanded the drug's indications between 1998 and 2003.

A major label addition came in 2003, when the FDA granted losartan an indication for stroke risk reduction in hypertensive patients with left ventricular hypertrophy. This was based on the LIFE trial (N=9,193), published in The Lancet in 2002, which showed a 13% relative risk reduction in the composite endpoint of cardiovascular death, stroke, and myocardial infarction for losartan versus atenolol (adjusted p=0.021) 1. The LIFE data gave losartan a labeling advantage over other ARBs that lacked stroke-specific evidence at the time.

Patent Portfolio and Exclusivity Strategy

Merck built a multi-layered patent estate around losartan that extended market exclusivity well beyond the compound patent. The base compound patent, U.S. Patent 5,138,069, covered the losartan molecule itself and was filed in 1990. A second patent, U.S. Patent 5,608,075, protected the specific potassium salt form. Additional formulation patents covered the hydrochlorothiazide combination product (Hyzaar) and specific tablet compositions.

This layered approach is common in pharmaceutical intellectual property strategy. Each patent created a separate barrier to generic entry, and Merck listed these patents in the FDA Orange Book, which triggers automatic 30-month stays on generic approvals when patent infringement suits are filed under the Hatch-Waxman Act 2.

The Hatch-Waxman framework gives brand manufacturers 45 days after receiving a Paragraph IV certification from a generic applicant to file suit. Merck exercised this right against early ANDA filers, including Teva Pharmaceutical Industries. The litigation centered on whether the proposed generic formulations infringed the salt-form and formulation patents. Court records show Merck pursued enforcement aggressively: the company filed patent infringement actions in the District of New Jersey against at least four generic manufacturers between 2005 and 2008.

Generic Entry and Paragraph IV Litigation

The first generic losartan reached the market in April 2010, when Teva's ANDA received final FDA approval following expiration of the key compound patent. Teva had been the first filer under Paragraph IV, earning 180 days of generic exclusivity as permitted by the Hatch-Waxman provisions 3.

That 180-day window meant only Teva could sell generic losartan potassium tablets during the initial post-patent period. Once this exclusivity expired, the FDA approved a wave of additional ANDAs. By the end of 2011, more than a dozen generic manufacturers had entered the market. Prices fell sharply. Average wholesale acquisition cost for losartan 50 mg dropped from approximately $3.50 per tablet (brand Cozaar) to under $0.15 per tablet within two years of multi-source generic availability, according to data from the National Average Drug Acquisition Cost (NADAC) survey published by the Centers for Medicare & Medicaid Services.

The Hyzaar combination product faced a slightly different timeline. Its additional formulation patents extended exclusivity for the fixed-dose combination beyond the losartan monotherapy date. Generic losartan/HCTZ entered the market in late 2010, several months after standalone losartan generics became available.

Settlement agreements between Merck and certain generic challengers followed the pattern seen across the pharmaceutical industry during this era. While specific financial terms remained confidential, the Federal Trade Commission scrutinized several ARB-related settlements as part of its broader investigation into "pay-for-delay" agreements 4. The FTC's annual reports on pharmaceutical patent settlements documented the losartan-related agreements alongside similar cases involving other blockbuster drugs losing exclusivity between 2008 and 2012.

The NDMA Contamination Crisis

Beginning in mid-2018, the FDA identified N-nitrosodimethylamine (NDMA) and related nitrosamine impurities in multiple ARB products, including losartan, valsartan, and irbesartan. NDMA is classified as a probable human carcinogen. The contamination was traced to changes in manufacturing processes at several active pharmaceutical ingredient (API) suppliers, primarily in China and India 5.

The FDA issued its first losartan-specific recall in March 2019, when Torrent Pharmaceuticals voluntarily recalled several lots of losartan potassium tablets after detecting NDMA levels above the interim acceptable intake limit of 96 nanograms per day. Over the following 18 months, the FDA posted more than 40 individual recall notices affecting losartan products from manufacturers including Hetero Labs, Macleods Pharmaceuticals, and Legacy Pharmaceutical Packaging 6.

The contamination did not originate from a single source. FDA investigators determined that at least three distinct chemical pathways could generate nitrosamine impurities during losartan API synthesis. One pathway involved the use of sodium nitrite in the presence of dimethylformamide (DMF) as a solvent. Another involved cross-contamination in shared manufacturing equipment previously used for other products. The FDA published detailed root-cause analyses and set permanent acceptable intake limits for NDMA (96 ng/day), NDEA (26.5 ng/day), and other nitrosamines in September 2020 7.

Dr. Janet Woodcock, then-Director of the FDA's Center for Drug Evaluation and Research, stated in a 2019 FDA press release: "We have been working around the clock to address the ARB contamination issue and ensure patients have access to safe medications. The FDA will not allow products with unacceptable levels of nitrosamine impurities to remain on the market" 8.

Class-Action Litigation and MDL Consolidation

The NDMA recalls generated a wave of personal injury and consumer protection lawsuits. Plaintiffs alleged that long-term exposure to nitrosamine-contaminated losartan and other ARBs increased cancer risk. The Judicial Panel on Multidistrict Litigation consolidated valsartan-related cases (which included losartan claims) into MDL No. 2875, assigned to Judge Robert B. Kugler in the U.S. District Court for the District of New Jersey.

As of early 2026, the MDL encompasses thousands of individual plaintiff claims. Defendants include API manufacturers (Zhejiang Huahai Pharmaceutical, Hetero Labs, Aurobindo Pharma), finished dosage form manufacturers (Torrent, Prinston, Solco Healthcare), and certain retail pharmacy chains. The litigation has produced extensive discovery regarding manufacturing quality controls, FDA inspection findings, and internal corporate communications about impurity testing.

Separate from the personal injury claims, several state attorneys general filed consumer protection actions against generic ARB manufacturers. These suits alleged violations of state consumer fraud statutes and sought refunds for patients who purchased contaminated products. The New Mexico Attorney General's office was among the first to file such an action in 2019, and at least six additional states followed.

The financial exposure for defendants remains significant. While no bellwether trials have reached verdict as of May 2026, pretrial rulings have allowed causation experts to testify based on established NDMA carcinogenicity data from animal models and epidemiological analyses. Defense motions to exclude plaintiff expert testimony on general causation were denied in key Daubert hearings during 2024 9.

FDA Manufacturing Reforms Post-NDMA

The NDMA crisis prompted the FDA to implement several permanent regulatory changes affecting the entire generic drug supply chain. In February 2021, the FDA issued final guidance requiring all pharmaceutical manufacturers to assess their products for potential nitrosamine contamination risk, regardless of drug class. Companies had to submit risk assessments and, where appropriate, confirmatory batch testing data 10.

The agency also increased the frequency of pre-approval inspections for API manufacturers in countries with high ARB production volume. FDA inspection data shows that warning letters issued to Indian and Chinese API facilities increased by approximately 35% between 2019 and 2021 compared with the 2016 to 2018 baseline. The agency expanded its use of "refuse to file" actions for ANDAs that did not adequately address nitrosamine risk.

For losartan specifically, the FDA now requires all ANDA holders to include validated nitrosamine testing methods in their drug master files. Acceptable limits were formalized in ICH M7(R2) guidelines, which the FDA adopted by reference. Testing must cover NDMA, NDEA, NMBA, and NIPEA at minimum, with reporting thresholds set at 10% of the acceptable daily intake 11.

These regulatory actions produced measurable supply chain effects. At least three smaller generic manufacturers withdrew their losartan ANDAs rather than invest in the required analytical upgrades. The number of active ANDA holders decreased from 26 in early 2019 to 21 by mid-2021, though it has since recovered to approximately 23 as of 2025.

Current Label and Ongoing Safety Monitoring

The current losartan prescribing information carries indications for hypertension, diabetic nephropathy (in patients with type 2 diabetes and an elevated serum creatinine and proteinuria), and stroke risk reduction in hypertensive patients with left ventricular hypertrophy. The label includes a boxed warning regarding fetal toxicity, consistent with all drugs acting on the renin-angiotensin system 12.

Post-market safety surveillance through the FDA Sentinel System and the FDA Adverse Event Reporting System (FAERS) has not identified new safety signals for losartan beyond the well-characterized class effects of ARBs, which include hyperkalemia, hypotension, and acute kidney injury in susceptible populations. FAERS data through Q4 2025 show losartan's adverse event profile remains consistent with pre-approval clinical trial findings 13.

The European Medicines Agency (EMA) completed a parallel review of ARB nitrosamine contamination in 2019 and required similar testing and process controls across EU-authorized generics. The EMA's Committee for Medicinal Products for Human Use (CHMP) published its final assessment in April 2020, aligning acceptable intake limits with those adopted by the FDA 14.

Losartan remains one of the most prescribed antihypertensives in the United States. According to ClinCalc data derived from the IQVIA National Prescription Audit, losartan ranked as the 8th most dispensed drug in the U.S. in 2024, with more than 55 million prescriptions filled. The drug's wholesale cost for a 30-day supply of losartan 50 mg currently averages $2.50 to $4.00 across major wholesalers, making it one of the least expensive branded or generic antihypertensive options available.